Selected References
Paquette M, et al.
Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia.
Arterioscler Thromb Vasc Biol. 2021; 41:2632-2640
https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316106
Pearson GJ, et al.
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Can J Cardiol. 2021; 37:1129-1150
https://www.onlinecjc.ca/article/S0828-282X(21)00165-3/abstract
Sampson M, et al.
A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia.
JAMA Cardiol. 2020; 5:540-548
https://jamanetwork.com/journals/jamacardiology/fullarticle/2761953
Ruel I, et al.
Imputation of Baseline LDL-C Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.
Clin Chem. 2018; 64:355-362
http://clinchem.aaccjnls.org/content/64/2/355.long
Mancini GBJ, et al.
Diabetes for Cardiologists: Practical Issues in Diagnosis and Management.
Can J Cardiol. 2017; 33:366-377
http://www.onlinecjc.ca/article/S0828-282X(16)30734-6/abstract
Mancini GBJ, et al.
Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).
Can J Cardiol. 2016; 32(Suppl Issue 7):S35-S65
https://www.onlinecjc.ca/article/S0828-282X(16)00007-6/abstract
Anderson T, et al.
2016 Canadian Cardiovascular Society Guidelines for the management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.
Can J Cardiol. 2016; 32:1263-1282
http://www.onlinecjc.ca/article/S0828-282X(16)30732-2/abstract
McClelland RL, et al.
10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study).
J Am Coll Cardiol. 2015; 66:1643-1653
https://www.jacc.org/doi/full/10.1016/j.jacc.2015.08.035
Genest J, et al.
Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia.
Can J Cardiol. 2014; 30:1471-1481
http://www.onlinecjc.ca/article/S0828-282X(14)01443-3/abstract
Mancini GBJ, et al.
Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease.
Can J Cardiol. 2014; 30:837-849
http://www.onlinecjc.ca/article/S0828-282X(14)00356-0/abstract
Rosenson R, et al.
An Assessment by the Statin Muscle Safety Task Force: 2014 Update.
J Clin Lipidol. 2014; 8:S58-S71
http://www.lipidjournal.com/article/S1933-2874(14)00160-3/abstract
Anderson T, et al.
2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult - 2012 recommendations.
Can J Cardiol. 2013; 29:151-167
https://www.onlinecjc.ca/article/S0828-282X(12)01510-3/abstract
Martin S, et al.
Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile.
JAMA. 2013; 310:2061-2068
https://jamanetwork.com/journals/jama/fullarticle/1779534
Stone J, et al.
Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Vascular Protection in People with Diabetes.
Can J Diabetes 2013; 37(Suppl 1):S100-S104
https://www.canadianjournalofdiabetes.com/article/S1499-2671(13)00031-2/abstract
Mancini GBJ, et al.
Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference.
Can J Cardiol. 2011; 27:635-662
http://www.onlinecjc.ca/article/S0828-282X(11)00351-5/abstract
Reiner Z, et al.
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Eur Heart J. 2011; 32:1769-1818
https://academic.oup.com/eurheartj/article/32/14/1769/528352
Sniderman A, et al.
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.
Nat Rev Endocrinol. 2010; 6:335-346
http://www.nature.com/nrendo/journal/v6/n6/full/nrendo.2010.50.html
Alberti KGMM, et al.
Harmonizing the Metabolic Syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
Circ. 2009; 120:1640-1645
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.109.192644
D'Agostino R, et al.
General cardiovascular risk profile for use in primary care: the Framingham Heart Study.
Circ. 2008; 117:743-753
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.699579
Ridker P, et al.
C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds risk score for men.
Circ. 2008; 118:2243-2251
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.108.814251
de Graaf J, et al.
A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.
Nat. Clin. Pract. Endocrinol. Metab. 2008; 4:608-618
https://www.ncbi.nlm.nih.gov/pubmed/18838971
Ridker P, et al.
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds risk score.
JAMA. 2007; 297:611-619
https://jamanetwork.com/journals/jama/fullarticle/205528
Jolliffe C, et al.
Distribution of lipoproteins by age and gender in adolescents.
Circ. 2006; 114:1056-1062
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.106.620864
Jones P, et al.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial).
Am J Cardiol. 2003; 92:152-160
https://www.ajconline.org/article/S0002-9149(03)00530-7/abstract
Gagne C, et al.
Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
Am J Cardiol. 2002; 90:1084-1091
https://www.ajconline.org/article/S0002-9149(02)02774-1/abstract
Jones P, et al.
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Am J Cardiol. 1998; 81:582-587
https://www.ajconline.org/article/S0002-9149(97)00965-X/abstract
Heiss G, et al.
Lipoprotein-cholesterol distributions in selected North American populations: The Lipid Research Clinics Program Prevalance Study.
Circ. 1980; 61:302-315
https://www.ahajournals.org/doi/10.1161/01.CIR.61.2.302